Phase 3 ADVANCE OUTCOMES trial on ralinepag succeeds

Robyn Kalda
Jul 29
1 min read

Patients with pulmonary arterial hypertension who took ralinepag in addition to their usual treatment were less likely to have their disease get worse than those who took a placebo. However, more people stopped taking ralinepag because of side effects.

Read the Lancet article

Recent Posts

Endoplasmic reticulum stress induces a pathway that accelerates PAH progression

This study found that endoplasmic reticulum stress in lung blood vessels may contribute to pulmonary arterial hypertension (PAH) by triggering pyroptosis and damaging blood vessels. In rats, blocking

More severe functional limitations are associated with higher social isolation

Functional disability, but not chronic disease category or chronic pain, was independently associated with lower social support. Social isolation among Canadian adults is more closely associated with

Smartphone data can support earlier detection of PAH

Researchers looked at smartphone data from 109 participants in the UK. Software was trained to distinguish idiopathic pulmonary hypertension (IPAH) and did so correctly at least 75% of the time. This

Comments